The incidence of the disease continues to increase in the female population at an alarming rate. Modern medicine has made little impact on the natural history of the condition, surgery still offering the best chance of cure to a small minority of patients with resectable tumours. Intensive combination chemotherapy has improved life expectancy in some patients with small cell lung cancer, but long term survival in this group is rare.
Although few important advances in the clinical management of the condition have been seen in the past decade, there has been an explosion of information on the basic cellular and molecular biology of the disease. This research has been facilitated by technological developments that have made it possible to grow human lung cancers for prolonged periods in the laboratory. In vitro and in vivo models have allowed both the study of the biological characteristics of the disease and assessment of the chemosensitivity of individual tumours to be performed in the laboratory.
Most of this progress has originated from cancer research establishments engaged in basic laboratory research. Few reports of this work have appeared in respiratory medicine publications, and it is disappointing that more of the respiratory physicians and thoracic surgeons who spend much of their time treating patients with lung cancer are not working in this exciting area of research. This article, the first of three on the study of lung cancer in the laboratory, reviews the methods by which cancer cells can be grown in the laboratory to provide models of human lung cancer. group.bmj.com on August 28, 2017 -Published by http://thorax.bmj.com/ Downloaded from isolation procedures and specialised husbandry techniques required to ensure a healthy colony. Their improved receptivity for human tumours, however, outweighs these problems.
CHARACTERISTICS OF LUNG CANCER XENOGRAFTS
Many reports have described the establishment and maintenance of lung cancer xenograft lines in nude mice,32-35 thymectomised irradiated mice,2936 and other animal models.24 Successful growth from clinical specimens has been achieved in 44-78% of tumours from reported series. There is little difference in growth between the various histological types of lung cancer or between primary and metastatic tumour. Surprisingly, small cell tumours usually prove the most difficult to establish.
Since the size of subcutaneously implanted xenografts can be easily measured with calipers, much is known about their growth rate. Most workers report doubling times in established xenografts of between six and 29 days.2937 The exact reason for the wide range of doubling times is unclear. Growth rates vary with histological type but, rather surprisingly, small cell xenografts do not have the shortest doubling tie29 33 37 time.
It is essential for human lung cancer xenografts to maintain the characteristics of the original donor tumour if they are to provide a relevant laboratory model for the study of human lung cancer. Several workers have verified that serially passaged tumours retain the correct chromosome complement and histological features similar to those of their donor tumour.29 34 36 37 The persistence of functional activity, such as ectopic hormone production by small cell lung cancer, has also been found when these tumours are grown in mice. Shimosato et a134 grew a small cell lung cancer tumour from a patient with inappropriate secretion of antidiuretic hormone and showed evidence of the production of adrenocorticotrophic hormone (ACTH) and / melanocyte stimulating hormone 10 months later in the xenograft. In a larger study38 ACTH Fergusson , Smyth into experimental animals, even when xenografts are allowed to grow to large sizes. Cachexia is now thought to be mediated in patients by a protein named cachectin (tumour necrosis factor) produced by host macrophages.39 Considerable variation is observed between different species of mammals, both in the sensitivity to administered cachectin and in the amounts of cachectin produced endogenously after challenge with endotoxin. The production and pathophysiological effects of this factor in immunocompromised rodents bearing human tumours have not been extensively studied.
The other major discrepancy lies in the fact that human malignant tumours frequently appear to lose their ability to metastasise when transplanted into experimental animals. The reason for this is unclear, although it has been suggested that the site and method of implantation may be important.40 4' The degree of immunosuppression of the host also appears to be critical in the development of metastases40; different strains of nude mice are known to show different levels of immunosuppression, the number of NK cells perhaps having a vital role.42 To overcome this problem interest is now being shown in the development of animal models of lung cancer with metastatic potential.22
These new developments should provide relevant laboratory tools to help us to understand the biology of lung cancer and hence to allow more effective treatments to be designed in the future.
